Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

BACKGROUND: Bevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation. In recent years, bevacizumab biosimilar has received marketing approval based on the results of phase III clinical studies. However, more...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhiting, Zhao, Luqing, Xia, Guohao, Lu, Jianwei, Shen, Bo, Zhou, Guoren, Wu, Fenglei, Hu, Xiao, Feng, Jifeng, Yu, Shaorong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868544/
https://www.ncbi.nlm.nih.gov/pubmed/36698393
http://dx.doi.org/10.3389/fonc.2022.1036906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868544/
https://www.ncbi.nlm.nih.gov/pubmed/36698393
http://dx.doi.org/10.3389/fonc.2022.1036906

Ejemplares similares